A Phase 1 Open-label Study of KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Padnarsertib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 21 Aug 2023 Status changed from suspended to recruiting.
- 02 Aug 2023 Status changed from recruiting to suspended and the reason the study was stopped was reported as other.
- 30 Aug 2021 Status changed from not yet recruiting to recruiting.